Abbott Molecular Inc.

Ventana Medical Systems, Inc.

Vysis, Inc.

Amoco Corporation

Abbott Laboratories Corporation

Mayo Foundation for Medical Education and Research

University of California

Other

Rush University Medical Center

Rush-presbyterian-st. Luke's Medical Center

Mayo Medical Ventures

Larry E Morrison

Irina A Sokolova

Jerome W Kosmeder, Ii

Michael L Bittner

Mona S Legator

Steven A Seelig

Ekaterina Pestova

Kevin C Halling

John S Coon

Garfield P Royer

Susan S Jewell

Christopher Bieniarz

William Kenneth Day

Brian Daniel Kelly

Mark Lefever

Walter E King

Eric J May

Kenneth A Cruickshank

Nelson Alexander

Stacey Stanislaw

Lou Dietz

Anne Pedata

Alicia Algeciras-Schimnich

John C Russell

Shihai X Huang

Michael J Heller

Klara Abravaya

John A Salituro

John R Hackett

Ka-Cheung X Luk

Boris C Bastian

Sedide Ozturk

Ying Zhang

Robert W Jaekel

Gregory Gores

Lewis Roberts

Jesse S Voss

Lisa M Peterson

Shannon Brankley

Anna O'hare

Emily Barr Fritcher

Benjamin Kipp

Jesse Voss

Boris Bastian

W Jerome Kosmeder

D Brian Kelly

Irina Sokolova

Kevin Halling

William Day

Eric May

Jerome W Kosmeder

Disclosed herein are embodiments of imaging biological specimens. An imaging system can include a microscope for directly viewing the biological specimen and a multi-spectral imaging apparatus for outputting digitally enhanced images, near-video rate imaging, and/or videos of the specimen. An imaging system can include a digital scanner that digitally processes images to produce a composite image with enhanced color contrast of features of interest.

Digitally enhanced microscopy for multiplexed histology

Disclosed embodiments concern a composition comprising DAB chromogen, and/or derivative thereof, a stabilizer, and polymer capable of preventing or reducing DAB precipitation relative to a composition that does not comprise the polymer. Also disclosed herein is a method for using the disclosed composition and embodiments of a kit.

Polymer stabilization of chromogen solutions

Disclosed herein are embodiments of a signaling conjugate, embodiments of a method of using the signaling conjugates, and embodiments of a kit comprising the signaling conjugate. The disclosed signaling conjugate comprises a latent reactive moiety and a chromogenic moiety that may further comprise a linker suitable for coupling the latent reactive moiety to the chromogenic moiety. The signaling conjugate may be used to detect one or more targets in a biological sample and are capable of being covalently deposited directly on or proximally to the target. Particular disclosed embodiments of the method of using the signaling conjugate comprise multiplexing methods.

Signaling conjugates and methods of use

The present invention is based on the discovery of methods and combinations of probes to chromosomal regions that are gained or lost or imbalanced in melanoma that provide highly specific and sensitive assays for the detection of melanoma cells.

Methods and probe combinations for detecting melanoma

An imaging system that can include a microscope for directly viewing a biological specimen and a multi-spectral imaging apparatus for outputting digitally enhanced images, near-video rate imaging, and/or videos of the specimen. An imaging system that can include a digital scanner that digitally processes images to produce a composite image with enhanced color contrast of features of interest.

The methods and compositions described herein address the need for diagnostic method that could be offered to women during yearly checkups to allow for early detection, diagnosis and classification, and treatment of endometrial cancer. In addition, these methods and compositions address the current need for improving diagnostic accuracy of biopsy procedures in symptomatic patients.

Detection of chromosomal abnormalities associated with endometrial cancer

A double-stranded nucleic acid hybridization probe and methods of using the same are described. The probe described is particularly suited for real-time RT-PCR reactions and has high tolerance to mismatches.

Double stranded linear nucleic acid probe

Methods of using probes and probe sets for the detection of high grade dysplasia and carcinoma in cervical cells are described. Methods of the invention include hybridizing one or more chromosomal probes to a biological sample obtained from a subject and detecting the hybridization pattern of the chromosomal probes to the sample to determine whether the subject has high grade dysplasia or carcinoma. Methods of the invention also include preliminary screening the cells for a marker associated with a risk for cancer, and preferably involves screening for HPV infected cells by in situ hybridization using an HPV probe mixture.

Detection of high grade dysplasia in cervical cells

A method to detect prostate cancer comprising contacting a sample of prostate cells from the patient with a set of detectably labeled probes under hybridization conditions and determining the presence of chromosomal abnormalities in prostate tumor tissue, PIN (intra-epithelial neoplasia), histologically benign tissue and benign prostatic hyperplasia (BPH); a method to combine immunofluorescence and FISH (IF-FISH) to facilitate the assessment of chromosomal abnormalities; a set of probes; and a kit comprising the set of probes and instructions for diagnosing prostate cancer in a patient.

Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

Methods of screening a sample for a predisposition for forming an EGFR-associated cancer and the presence of EGFR (v3) contained therein are described. The methods include the steps of obtaining a sample containing a plurality of cells and hybridizing a first set of labeled chromosomal probes and a second set of labeled chromosomal probes to the sample. The first set of labeled chromosomal probes specific to chromosome 7, and the second set of labeled chromosomal probes is a labeled EGFR(v3)-probe. The first and second sets of labeled chromosomal probes include different labels to permit identification of the first and second sets of labeled chromosomal probes hybridized to the sample. The method includes calculating the number of signals of the first and second sets labeled chromosomal probes on an individual cell basis and determining a predisposition for forming an EGFR-associated cancer and the presence of EGFR (v3) contained therein based upon those calculations.

Method and compositions for detecting epidermal growth factor receptor variant forms in cancer cells

The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of &#x2265;0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals &#x2265;1.1 versus MYC/5p15 ratio of &#x3c;0.80 or 5p15/CEP6&#x3c;1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery.

Diagnostic methods for determining prognosis of non-small cell lung cancer

Growing community of inventors

Glen Ellyn, IL, United States of America

Larry E Morrison